Why is a payday loan right for you Payday loan 50 up to
Payday loans uk

Editing Genes for a Cure

Posted on April 11, 2014 by in LifeGuide, Treatment Horizons

Close to the Edit A functional cure candidate modifies genes to create HIV-resistant cells by Chael Needle Gary Blick, MD, AAHIVS, Medical & Research Director of CIRCLE CARE Center and Chief Medical Officer of World Health Clinicians, doesn’t throw the word “cure” around lightly. As an HIV physician for over thirty years, he remembers when [...]

Cure News

Posted on April 3, 2014 by in Destination: Cure, LifeGuide

News of the Day The latest reports on HIV cure research show momentum by Jeannie Wraight Here’s a look at some of the HIV cure headlines over the past couple months. The ever-growing momentum towards a cure, particularly funding for cure initiatives, is encouraging. Obama redirects $100 million towards HIV cure research At a White [...]

Race to the Hep C Cure

Posted on March 24, 2014 by in Hep Talk, LifeGuide

Race to the Cure Who are the biggest players now in eradicating hepatitis C? by Larry Buhl Beyond the implementation of the Affordable Care Act, one of the biggest healthcare stories of 2013 was the emerging race of pharmaceutical companies to bring new drugs to the market to cure hepatitis C. The advent of direct-acting [...]

Mighty Mouse

Posted on March 20, 2014 by in LifeGuide, Treatment Horizons

Mighty Mouse A humanized BLT mouse model creates a vital platform for drug discovery by Chael Needle In the early stages of drug discovery, many candidates that show promise of effective anti-HIV activity may be in the running. But which ones deserve to move on? That question is answered in part by those researchers who [...]

Coffee & HCV

Posted on March 6, 2014 by in Hep Talk, LifeGuide

Coffee Talk Two studies shed light on HCV prevention & treatment by Larry Buhl A study on the long-term infectiousness of the hepatitis C virus (HCV) has implications for healthcare workers, IV drug users, and tattoo artists, while another study shows the benefits of coffee and tea on liver inflammation in chronic hepatitis C patients. [...]

Host Restrictive Factors

Posted on March 5, 2014 by in LifeGuide, Treatment Horizons

The Deeper End of the Ocean Host restrictive factors create research excitement by Mariel Selbovitz, MPH, and David Miller The doors on viral host restrictive factors (HRFs), the means by which our cells are designed to resist infection, are being pried open by scientists who see the next round of therapeutic advances for treating HIV [...]

HCV Serosorting

Posted on January 24, 2014 by in Hep Talk, LifeGuide

Testing, Testing Serosorting is common for IV drug users who know their HCV status by Larry Buhl A new study shows IV drug users who know they carry the hepatitis C virus are likely to consider their serostatus when deciding whether and with whom to share injection equipment. The results, published in the December 15, [...]

David Evans

Posted on January 22, 2014 by in Destination: Cure, LifeGuide

Risk & Reward Activist David Evans weighs in on next steps in cure advocacy & research by Jeannie Wraight In the late 1980s and throughout the ’90s, AIDS treatment activism helped dramatically speed up AIDS research and the drug approval process, saving countless people from illness and certain death. Now, in 2013, some of the [...]

HPV Immunotherapy Research

Posted on January 13, 2014 by in LifeGuide, Treatment Horizons

Warts & All An immunotherapy candidate seeks to address complications from HPV by Chael Needle Human papillomavirus (HPV) is the most common sexually transmitted infection, but, according to the CDC, most who are infected never develop symptoms nor health problems. Keep in mind, though: a history of anogenital warts in men and women has been [...]

Direct-Acting Antivirals & HCV

Posted on December 31, 2013 by in Hep Talk, LifeGuide

Hep Talk by Larry Buhl Two Agents New direct-acting antivirals cross a major hurdle                       The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) in October gave unanimous recommendations for approval of two next-generation direct-acting antivirals (DAAs) for hepatitis C, Janssen’s [...]